Please login to the form below

Not currently logged in

Aesica to buy UCB's German/ Italian sites

Leading UK pharmaceutical manufacturer, Aesica, has agreed to acquire UCB's manufacturing businesses in Germany and Italy

UCB and Aesica have agreed that Aesica will acquire current UCB manufacturing businesses in Germany and Italy.

The agreement includes the manufacturing sites in the German cities of Monheim and Zwickau, as well as Pianezza in Italy, and is part of UCB's strategy to optimise its manufacturing network in line with the evolution of its portfolio. The move will also secure the long-term supply of UCB's products and a future for the sites and their employees, according to UCB CEO Roch Doliveux.

Doliveux stated: "UCB's product portfolio has been changing significantly, which reduced UCB's need for large manufacturing capacity for chemical entities, while increasing its biotech requirements."

Approximately 600 employees in the three affected sites will be transferred to Aesica.

CEO of Aesica, Dr Robert Hardy, said: "The acquisition of the three manufacturing sites from UCB is strategically crucial for Aesica as we extend and enhance our current offering and presence in Europe. We hope to fully utilise the expertise and knowledge across the current team at UCB to achieve our vision of becoming the leading supplier of formulated products and active pharmaceutical ingredients to the global pharmaceutical and biotechnology industries.”

Subject to antitrust clearance, closing is expected for the first quarter of 2011. UCB's financial outlook for 2010 remains unchanged.

15th December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...